Experience

Fate Therapeutics Inc

• United States
• Biotechnology Research
• 200 - 300 Employee

• • Jan 2023 - Present

• • Apr 2021 - Jan 2023

  Responsible for translating preclinical hypothesis into clinical biomarker strategies for solid tumor studies from a broad portfolio of cell assets Phase 1/2 clinical trials. Lead a cross-functional project team defining biomarker testing plans and translating scientific discoveries into clinical strategies. Provide scientific leadership to peers in assigned project teams including discovery scientists, clinical researchers, bioinformatics scientists. Identify biomarker assays for clinical implementation, including the discovery and validation of PK and PD biomarkers. Translate biology insights into plans to support clinical development and product enhancement. Show less



Bristol Myers Squibb

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• • Aug 2020 - Mar 2021

  Responsible for integrating translational research and clinical development, development a biomarker strategy in alignment with clinical development objectives, leading efforts for data generations, interpretation and communication to the development teams. Engages functional groups to develop, champion, implement and align biomarker strategies for development projects in support of the overall R&D portfolio goals. Delivers high quality biomarker strategies for target engagement, pharmacodynamics endpoints and patient selection. Engages team members to ensure alignment of biomarker strategies with clinical operational plans with functional area capabilities. Effectively interfaces with functional areas to ensure strategic alignment and to identify resources needed to deliver on biomarker goals. Show less

• • Apr 2018 - Aug 2020

  Help to advance Bristol Myers Squibb’s O/IO pipeline through the strategic application of cutting edge approaches, supporting all aspects of Drug Discovery, Early and Late development and Biomarker Assay development. Led data integration efforts to provide robust data analysis results for the entire BMS Early Drug Development portfolio.Served as Translational Bioinformatics Lead for more than 10 Early Development ProgramsExecuted clinical trial analysis for multiple Late Development Programs (Bladder, NSCLC, Melanoma, HNSCC, GI, HCC).Served as a Scientific Lead for BMS GEP assay development program (RUO to IUO assay validation).Discovered novel resistance mechanism in IO and initiated Discovery programs. Show less

• • Nov 2015 - Apr 2018



National Cancer Institute (NCI)

• United States
• Research Services
• 700 & Above Employee

• Visiting Fellow

  • Sep 2012 - Nov 2015

  Development of computational biology methods, models and bioinformatics systems to support precision medicine in oncology. Identification of novel driver mutations and therapeutic options in melanoma. Analysis of clinical trial data to identify ovarian cancer patients who would benefit from PARP-inhibitor therapy. Development of a publicly available pre-clinical, drug screening database for the National Cancer Institute. Identification of novel pathogenic pathways in renal cell carcinoma. Show less



Hungarian Academy of Sciences

• Research Services
• 200 - 300 Employee

• Research Fellow

  • Oct 2010 - Sep 2012

  Analysis of gene expression changes in molecular networks by artificial intelligence techniques. Development of a dynamic network analysis model, to identify the most influential genes in disease pathogenesis. Analysis of microRNA expression changes in pituitary tumors. Molecular and systems biology analysis adrenocortical cancers and pheochromocytoma. Systems biology analysis and molecular comparison of neuroblastoma and phaeochromocytoma tissues. Analysis of gene expression changes in molecular networks by artificial intelligence techniques. Development of a dynamic network analysis model, to identify the most influential genes in disease pathogenesis. Analysis of microRNA expression changes in pituitary tumors. Molecular and systems biology analysis adrenocortical cancers and pheochromocytoma. Systems biology analysis and molecular comparison of neuroblastoma and phaeochromocytoma tissues.



Semmelweis University

• Hospitals and Health Care
• 700 & Above Employee

• Physician resident

  • Sep 2009 - Oct 2010